Pemvidutide: Research & Evidence
Emerging EvidencePublished research, clinical trial data, and evidence grading for Pemvidutide across studied indications.
Back to Pemvidutide overviewResearch Summary
Pemvidutide has approximately 3-5 RCTs completed or ongoing across obesity, MASH, and alcohol use disorder indications. The Phase 2b IMPACT trial achieved its primary endpoint with 59.1% MASH resolution without fibrosis worsening at 24 weeks (PMC12529369). The Phase 2 MOMENTUM trial demonstrated meaningful weight loss at 48 weeks. Altimmune has expanded into AUD (RECLAIM trial) and ALD (RESTORE trial) — innovative applications of GLP-1/glucagon dual agonism. FDA Fast Track designation was granted for MASH. As of March 2026, pemvidutide remains investigational with no FDA approval, and Phase 3 trials are planned pending 48-week IMPACT data.
Evidence by Indication (3 indications)
| Indication | Tier | Trials | Summary |
|---|---|---|---|
| MASH resolution | Tier B | 1 | Phase 2b IMPACT trial showed 59.1% resolution; Phase 3 planned |
| Obesity / weight loss | Tier C | 1 | Phase 2 MOMENTUM trial showed meaningful weight loss |
| Alcohol use disorder | Tier D | 1 | Phase 2 RECLAIM trial recruiting as of 2025 |
Graded using our evidence tier methodology.
Higher score = larger gap between therapeutic potential and available clinical evidence.
Citations (2 sources)
- 1. Pemvidutide in metabolic dysfunction-associated steatohepatitis: Phase 2b IMPACT trial 24-week results Clinical Trial
Altimmune investigators (2025), Hepatology
- 2. Pemvidutide in adults with obesity: the Phase 2 MOMENTUM trial Clinical Trial
Altimmune investigators (2024), Obesity